Alpha Wavelet Power as a Biomarker of Antidepressant Treatment Response in Bipolar Depression

AbstractAdverse Childhood Experiences (ACE) are a well-known risk-factor for depression. Additionally, (high-sensitive) C-reactive Protein (hsCRP) is elevated in subgroups of depressed patients and high following ACE. In this context the literature considers hsCRP and ACE to be associated with treatment resistant depression. With the data being heterogenous, this study aimed to explore the associations of ACE, hsCRP levels and response to antidepressant treatment in uni- and bipolar depression. N = 76 patients diagnosed with uni- or bipolar depression and N = 53 healthy controls were included. Treatment was over 6 weeks in an inpatient psychiatric setting within an observatory study design. Depressive symptoms were assessed by the Montgomery-Asberg Depression Rating Scale (MADRS), ACE were assessed by the Childhood Trauma Questionnaire (CTQ); the body-mass-index (BMI) and hsCRP were measured. HsCRP levels did not differ between the study population and the healthy controls. While the depressive symptoms decreased, the hsCRP levels increased. Sexual abuse was associated with significant higher and emotional abuse with lower levels of hsCRP after 6 weeks. The baseline hsCRP levels and the ACE subgroups did not show significant associations with the treatment response in unipolar depressed patients. The long-lasting effects of specific forms of ACE may have relevant impact on inflammation, supporting hsCRP to be a suitable biomarker. With ACE and hsCRP not showing any significant associations with treatment response in the unipolar depressed subgroup, a more differentiate research concerning biomarkers and treatment regimens is needed when talking about treatment response.

Download Full-text

Faculty Opinions recommendation of Early prediction of acute antidepressant treatment response and remission in pediatric major depressive disorder.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1160666.622058 ◽

2009 ◽

Author(s):

Charles Zeanah

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Treatment Response ◽

Antidepressant Treatment ◽

Early Prediction ◽

Major Depressive

Download Full-text

Biomarkers of ketamine’s antidepressant effect: a clinical review of genetics, functional connectivity, and neurophysiology

Chronic Stress ◽

10.1177/24705470211014210 ◽

2021 ◽

Vol 5 ◽

pp. 247054702110142

Author(s):

Alexandra A. Alario ◽

Mark J. Niciu

Keyword(s):

Treatment Response ◽

Antidepressant Treatment ◽

A Priori ◽

Antidepressant Effect ◽

Aspartate Receptor ◽

Neurophysiological Studies ◽

All Cause Mortality ◽

Antidepressant Efficacy ◽

Glutamate Modulators ◽

Response Biomarkers

Major depressive disorder (MDD) is one of the leading causes of morbidity and all-cause mortality (including suicide) worldwide, and, unfortunately, first-line monoaminergic antidepressants and evidence-based psychotherapies are not effective for all patients. Subanesthetic doses of the N-methyl-D-aspartate receptor antagonists and glutamate modulators ketamine and S-ketamine have rapid and robust antidepressant efficacy in such treatment-resistant depressed patients (TRD). Yet, as with all antidepressant treatments including electroconvulsive therapy (ECT), not all TRD patients adequately respond, and we are presently unable to a priori predict who will respond or not respond to ketamine. Therefore, antidepressant treatment response biomarkers to ketamine have been a major focus of research for over a decade. In this article, we review the evidence in support of treatment response biomarkers, with a particular focus on genetics, functional magnetic resonance imaging, and neurophysiological studies, i.e. electroencephalography and magnetoencephalography. The studies outlined here lay the groundwork for replication and dissemination.

Download Full-text

Peripheral vascular endothelial growth factor level is associated with antidepressant treatment response: Results of a preliminary study

Journal of Affective Disorders ◽

10.1016/j.jad.2012.09.006 ◽

2013 ◽

Vol 144 (3) ◽

pp. 269-273 ◽

Cited By ~ 26

Author(s):

Zsuzsa Halmai ◽

Peter Dome ◽

Judit Dobos ◽

Xenia Gonda ◽

Anna Szekely ◽

...

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Treatment Response ◽

Antidepressant Treatment ◽

Vascular Endothelial ◽

Peripheral Vascular ◽

Factor Level ◽

Preliminary Study ◽

Endothelial Growth Factor

Download Full-text

Antidepressant Treatment Response in Depressed Hypothyroid Patients

Psychiatric Services ◽

10.1176/ps.40.9.954 ◽

1989 ◽

Vol 40 (9) ◽

pp. 954-956

Author(s):

Mark J. Russ ◽

Sigurd H. Ackerman

Keyword(s):

Treatment Response ◽

Antidepressant Treatment ◽

Hypothyroid Patients

Download Full-text

Assessment of mature serum brain-derived neurotrophic factor (BDNF) is not superior to total serum BDNF in prediction of antidepressant treatment outcome

European Psychiatry ◽

10.1016/j.eurpsy.2016.01.1480 ◽

2016 ◽

Vol 33 (S1) ◽

pp. S410-S410 ◽

Cited By ~ 1

Author(s):

A. Eckert ◽

T. Mikoteit ◽

J. Beck ◽

U.M. Hemmeter ◽

S. Brand ◽

...

Keyword(s):

Treatment Outcome ◽

Treatment Response ◽

Rating Scale ◽

Antidepressant Treatment ◽

Serum Levels ◽

Total Serum ◽

Enzyme Linked Immunosorbent Assay ◽

Functional Link ◽

Neurotrophic Activity ◽

Serum Bdnf

BackgroundSerum BDNF levels are decreased in major depressive disorder (MDD) and tend to normalize under antidepressant treatment, serving as a treatment outcome predictor. BDNF is initially synthetized as precursor protein proBDNF and is cleaved to mature BDNF (mBDNF) while only the latter exerts neurotrophic activity.AimThe aim was to explore if a specific enzyme-linked immunosorbent assay (ELISA) kit for mBDNF in serum would be superior to the unspecific assessment of total serum BDNF in predicting treatment response in MDD.MethodsTwenty-five patients with MDD underwent standardized treatment with duloxetine. Severity of depression was measured by Hamilton Depression Rating Scale (HDRS) at baseline (BL), after one (W1), two (W2) and six weeks (W6) of treatment. Treatment response was defined as a HDRS ≥ 50% reduction of BL score at W6. mBDNF and total BDNF serum levels were determined at BL, W1 and W2.ResultsA high and stable correlation was found between mBDNF and total BDNF serum levels over all measurements. The predictive value of mBDNF BL levels and mBDNFΔW1 to response was similar to that of total BDNF BL and total BDNFΔW1. The assessment of serum mBDNF was not superior to total BDNF in prediction of treatment outcome.ConclusionsNot only baseline total BDNF but also mBDNF is predictive to treatment outcome. The later might represent the main player in this respect, which supports the idea of a functional link between neuroplasticity and MDD.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Download Full-text